9.575

2.47% 0.295

Bioventus Inc (BVS)

Overview News Price History Option Chain Financials Discussions Forecast

Bioventus Inc stock is traded at $9.575, with a volume of 147.33K. It is up +2.47% in the last 24 hours and down -5.76% over the past month. Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.

Previous Close:

$9.28

Open:

$9.33

24h Volume:

147.33K

Relative Volume:

0.31

Market Cap:

$648.69M

Revenue:

$568.09M

Net Income/Loss:

$27.27M

P/E Ratio:

29.23

EPS:

0.3276

Net Cash Flow:

$71.41M

1W Performance:

-10.80%

1M Performance:

-5.76%

6M Performance:

+24.30%

1Y Performance:

+45.62%

1-Day Range:

$9.15

$9.575

1-Week Range:

$9.15

$11.00

52-Week Range:

$5.81

$11.25

Bioventus Inc Stock (BVS) Company Profile

Name

Bioventus Inc

Sector

Healthcare (1110)

Industry

Medical Devices (143)

Phone

(919) 474-6700

Address

4721 EMPEROR BOULEVARD, SUITE 100, DURHAM

Employee

940

Twitter

Next Earnings Date

2026-05-06

Latest SEC Filings

BVS's Discussions on Twitter

Compare BVS vs ABT, SYK, MDT, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BVS Bioventus Inc	9.575	628.70M	568.09M	27.27M	71.41M	0.3276
ABT Abbott Laboratories	86.05	152.25B	45.13B	6.28B	7.38B	3.5895
SYK Stryker Corp	311.25	121.33B	25.27B	3.34B	4.57B	8.6334
MDT Medtronic Plc	77.64	100.91B	35.48B	4.64B	5.41B	3.582
BSX Boston Scientific Corp	57.79	85.88B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	86.61	49.39B	6.30B	1.07B	1.09B	1.8406

Bioventus Inc Stock (BVS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-27-26	Initiated	CJS Securities	Market Outperform
Feb-09-26	Initiated	Barrington Research	Outperform
Jul-07-25	Initiated	Cantor Fitzgerald	Overweight
Dec-17-24	Upgrade	JP Morgan	Underweight → Neutral
Dec-07-23	Upgrade	Canaccord Genuity	Hold → Buy
Aug-09-23	Upgrade	Craig Hallum	Hold → Buy
Nov-22-22	Downgrade	Craig Hallum	Buy → Hold
Nov-09-22	Downgrade	Canaccord Genuity	Buy → Hold
Nov-09-22	Downgrade	JP Morgan	Overweight → Underweight
Mar-15-22	Initiated	Craig Hallum	Buy
Nov-15-21	Resumed	Morgan Stanley	Overweight
Nov-10-21	Resumed	JP Morgan	Overweight
Jul-01-21	Downgrade	Goldman	Buy → Neutral
Mar-08-21	Initiated	Canaccord Genuity	Buy
Mar-08-21	Initiated	Goldman	Buy
Mar-08-21	Initiated	JP Morgan	Overweight
Mar-08-21	Initiated	Morgan Stanley	Overweight

View All

Bioventus Inc Stock (BVS) Latest News

May 24, 2026

Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It - Benzinga

May 22, 2026

Bioventus Is Maintained at Outperform by Barrington Research - Moomoo

May 22, 2026

Bioventus Inc. Files Form 8-K: Corporate Details, Stock Information, and SEC Compliance for May 2026 - Minichart

May 22, 2026

May 21, 2026

FDA reclassifies Bioventus bone growth stimulator; company maintains 2026 outlook - Investing.com UK

May 21, 2026

FDA reclassifies Bioventus bone growth stimulator; company maintains 2026 outlook By Investing.com - Investing.com South Africa

May 21, 2026

Bioventus Inc stated in a filing with the SEC that expected adjustments to reimbursement policies related to the Exogen bone healing system are not anticipated to have a material impact on the company’s financial position for fiscal year 2026. - Bitget

May 21, 2026

According to documents submitted to the U.S. Securities and Exchange Commission, SEACOR Marine Holdings Inc. expects its newly built platform supply vessels to be delivered successively in the fourth quarter of 2026 and the first quarter of 2027. - Bitget

May 21, 2026

GE Vernova Inc. announces the acquisition of Robotech Automation to accelerate advancements in its robotics and automation capabilities. - Bitget

May 21, 2026

According to documents submitted to the U.S. Securities and Exchange Commission, the U.S. Food and Drug Administration completed the reclassification of Bioventus Inc.'s Exogen ultrasound bone healing system on April 16, 2026. - Bitget

May 21, 2026

FDA reclassifies bone growth stimulators; Bioventus says 2026 guidance unchanged - TradingView

May 21, 2026

CMS reimbursement shifts leave Bioventus (NASDAQ: BVS) 2026 guidance intact - Stock Titan

May 21, 2026

Is Bioventus (BVS) Stock Undervalued Right Now? - Yahoo Finance

May 21, 2026

May 18, 2026

Are Medical Stocks Lagging Bioventus (BVS) This Year? - Yahoo Finance

May 18, 2026

May 17, 2026

(BVS) Volatility Zones as Tactical Triggers - Stock Traders Daily

May 17, 2026

May 15, 2026

Bioventus (BVS) Q1 2026 Earnings: EPS $0.15 Beats EstimatesHot Community Stocks - Newser

May 15, 2026

Statutory Profit Doesn't Reflect How Good Bioventus' (NASDAQ:BVS) Earnings Are - Sahm

May 15, 2026

May 14, 2026

Bioventus' (NASDAQ:BVS) Solid Earnings Are Supported By Other Strong Factors - Yahoo Finance

May 14, 2026

May 09, 2026

Bioventus (BVS) Q1 2026 Earnings Transcript - AOL.com

May 09, 2026

May 08, 2026

Wall Street analysts see a 38.97% upside in Bioventus (BVS): Can the stock really move this high? - MSN

May 08, 2026

Wall Street Analysts See a 38.97% Upside in Bioventus (BVS): Can the Stock Really Move This High? - Yahoo Finance

May 08, 2026